Curious about Edwards Lifesciences (EW) Q3 Performance? Explore Wall Street Estimates for Key Metrics

Zacks
Abrir em Zacks
Curious about Edwards Lifesciences (EW) Q3 Performance? Explore Wall Street Estimates for Key Metrics

Analysts on Wall Street project that Edwards Lifesciences (EW) will announce quarterly earnings of $0.73 per share in its forthcoming report, representing an increase of 9% year over year. Revenues are projected to reach $1.68 billion, increasing 8% from the same quarter last year.

Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.

Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.

Given this perspective, it's time to examine the average forecasts of specific Edwards Lifesciences metrics that are routinely monitored and predicted by Wall Street analysts.

Based on the collective assessment of analysts, 'Net Sales by Product Group- Transcatheter Mitral and Tricuspid Therapies' should arrive at $195.98 million. The estimate indicates a year-over-year change of +35%.

Analysts' assessment points toward 'Net Sales by Product Group- Surgical Structural Heart' reaching $267.05 million. The estimate indicates a change of +3.5% from the prior-year quarter.

According to the collective judgment of analysts, 'Net Sales by Product Group- Transcatheter Aortic Valve Replacement' should come in at $1.21 billion. The estimate indicates a change of +5.1% from the prior-year quarter.

View all Key Company Metrics for Edwards Lifesciences here>>>

Over the past month, shares of Edwards Lifesciences have returned +10.9% versus the Zacks S&P 500 composite's +0.7% change. Currently, EW carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research